$GSK

The PASTEUR Act aims to create a subscription-style payment model for novel antibiotics, decoupling drug value from sales volume. This bill, if passed, will stabilize the market for antibiotic development, directly benefiting pharmaceutical companies focused on infectious disease research.

The PASTEUR Act establishes a subscription-style payment model for novel antibiotics, guaranteeing revenue for pharmaceutical companies developing new antimicrobial treatments. This de-risks R&D for antibiotics, driving investment and innovation in a critical healthcare area. Companies with strong antibiotic pipelines stand to gain significant, predictable revenue streams.

The 'Protecting Free Vaccines Act' aims to maintain free access to vaccines, which directly impacts the revenue models of pharmaceutical companies. This bill, if passed, will likely shift vaccine procurement costs to the federal government, maintaining demand for vaccine manufacturers.